Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2019-07-03 Director's Dealing
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states it is an announcement regarding 'Director/PDMR Shareholding'. It details purchases of ordinary shares by directors (Dr Paul Kerr, Alan Mawson, Sonya Ferguson) and includes mandatory disclosure tables required under EU Market Abuse Regulation (MAR). This type of filing, reporting insider transactions by directors/PDMRs, corresponds directly to the definition of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2019-07-03 English
Final Results
Earnings Release Classification · 100% confidence The document is an announcement dated July 2, 2019, titled 'Final results' for the year ended March 31, 2019, from Fusion Antibodies PLC. It contains key financial highlights (revenues, loss for the year, cash position), commentary from the CEO and Chairman, and a detailed Statement of Comprehensive Income comparing 2019 and 2018 results. This structure—a summary announcement of comprehensive annual financial performance—is characteristic of an Annual Report (10-K) or a very detailed Interim/Annual Report. Since the document covers the full fiscal year ('year ended 31 March 2019') and includes full financial statements (Statement of Comprehensive Income), it functions as the primary annual financial disclosure. Although it is presented via an RNS number, the content itself is the full annual results disclosure, making '10-K' (Annual Report) the most appropriate classification for the underlying report type being summarized/released, even if the release mechanism is RNS. Given the depth of financial detail provided, it goes beyond a simple Earnings Release (ER) or Interim Report (IR). It is the final, audited-style annual results. FY 2019
2019-07-02 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and contains details about a transaction involving a director (Chief Executive Officer) purchasing company shares. This specific type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing'. The presence of 'Director/PDMR Shareholding' and the transaction details confirm this classification, matching code DIRS.
2019-04-29 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1503 characters) and contains an 'RNS Number' and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange.' The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action announcement (like DIV or ER). Since it is a direct, non-standard regulatory announcement distributed via the RNS system, and it doesn't fit the definitions for AGM-R, 10-K, ER, CT, etc., the most appropriate classification is the general regulatory announcement fallback category, RNS.
2019-04-25 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1486 characters) and contains an 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange'. The content itself is a notification regarding a 'Price Monitoring Extension' for an auction call period, which is a specific, non-standard market operation announcement. Since it is a direct, short announcement disseminated via the RNS system and does not fit into specific categories like ER, 10-K, or DIV, it falls best under the general regulatory announcement category.
2019-04-25 English
Trading Update
Earnings Release Classification · 99% confidence The document is identified by the 'RNS Number' header and contains an 'RNS Number' (4068W), indicating it is a regulatory news service announcement from the London Stock Exchange. The content is a 'Year-end trading update' providing unaudited financial highlights (revenues, cash position) for the year ended 31 March 2019, along with operational updates. This format—a brief, periodic update on financial performance released via a regulatory news wire—most closely aligns with an Earnings Release (ER), which covers key highlights before a full report. However, since it is explicitly distributed via RNS and is a general trading update rather than a formal quarterly/interim report (IR) or a full annual report (10-K), the most appropriate classification for a general regulatory announcement of this nature, especially given the RNS context, is the general Regulatory Filings category (RNS), unless it perfectly matches ER. Since it provides key financial highlights for a period end, ER is a strong candidate, but RNS is the mechanism of delivery and a safe classification for non-standard regulatory updates. Given the content is a 'trading update' with financial highlights, it functions as an Earnings Release (ER). The presence of the RNS number confirms it is a regulatory filing, but the content type is an earnings update. FY 2019
2019-04-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.